IP Library Granted Patent US 9,176,126
Granted Patent B2
US 9,176,126 · App. 14/270,618 · Granted Nov 3, 2015

Systems and methods of sample processing and fluid control in a fluidic system

Inventors: Elizabeth A. Holmes (Palo Alto, CA); Shaunak Roy (Palo Alto, CA); Ian Gibbons; Shize Daniel Qi (Palo Alto, CA); Edmond Ku (Palo Alto, CA); Chris Todd (Palo Alto, CA); Melissa Takahashi (Palo Alto, CA); Bruce Johnson (Palo Alto, CA); Jeff Fenton (Palo Alto, CA); Keith Moravick (Palo Alto, CA); Uwe Springborn (Palo Alto, CA); Anthony Delacruz (Palo Alto, CA)
Assignee: Theranos, Inc.
G01N33/536A61B5/1411A61B5/1486A61B5/412A61B5/685G01N33/5302G01N33/573G01N2333/46G01N2333/91188G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,176,126
App. No.
14/270,618
Granted
Nov 3, 2015
Kind
B2
Abstract

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

Claims (17)

1. A method of detecting an analyte in a bodily fluid from a subject, comprising:

a) providing a fluidic device comprising a cartridge, said cartridge comprising a sample collection unit and an assay assembly, wherein said sample collection unit is configured to collect a sample of bodily fluid from said subject, and wherein said assay assembly comprises at least one reaction site containing a reactant adapted to reacts with said analyte;

b) metering a predetermined portion of said sample to be assayed in said sample collection unit;

c) allowing said predetermined portion of sample to react with assay reagents contained within said assay assembly to yield a signal indicative of the presence of said analyte in said sample; and

d) detecting said signal generated from said analyte collected in said sample of bodily fluid.

2. The method of claim 1 , further comprising mixing said predetermined portion of said sample with a diluent in said fluidic device after the metering step.

3. The method of claim 2 , wherein said mixing comprises diluting said predetermined portion of said sample with said diluent to yield a diluted sample.

4. The method of claim 3 , further comprising filtering said diluted sample before allowing said predetermined portion of sample to react with assay reagents.

5. The method of claim 3 , wherein said assay assembly comprises at least one reagent chamber and an actuatable valve assembly configured to control flow of the reagents out of said reagent chamber and into said at least one reaction site.

6. The method of claim 5 , further comprising actuating said actuatable valve assembly to permit said reagent to flow from said reagent chamber to said reaction site.

7. The method of claim 6 , wherein said actuatable valve assembly comprises an actuator pin and a sealing ball, and said actuating comprising actuating said actuator pin to displace said sealing ball.

8. The method of claim 1 , further comprising the step of quantifying the amount of said analyte present in said bodily fluid after said detecting step.

9. The method of claim 8 , further comprising the step of comparing the amount of said analyte present in said biologic fluid to a predetermined amount of said analyte.

10. The method of claim 1 , wherein said fluidic device communicates data relating to said signal via a wireless transmitter to an external device.

11. The method of claim 1 , wherein the analyte detected is indicative of at least one pharmacological parameter.

12. The method of claim 11 , further comprising cross-referencing medical records of said subject with the at least one pharmacological parameter to assistant a clinician in providing an individualized medical treatment.

13. The method of claim 4 , wherein said filtering comprises removing red blood cells from the diluted sample.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2023
From: LABRADOR DIAGNOSTICS LLC
To: GOLDEN DIAGNOSTICS TOP CORP.
Reel/Frame 064262/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2023
From: GOLDEN DIAGNOSTICS TOP CORP.
To: GOLDEN DIAGNOSTICS CORP.
Reel/Frame 064264/0393 →
CHANGE OF NAME Recorded Apr 7, 2020
From: THERANOS IP COMPANY LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052329/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2018
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 045101/0315 →
SECURITY INTEREST Recorded Dec 12, 2017
From: THERANOS IP COMPANY, LLC
To: FORTRESS CREDIT CORP.
Reel/Frame 044839/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: THERANOS INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 044838/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2015
From: HOLMES, ELIZABETH A; ROY, SHAUNAK; GIBBONS, IAN; QI, SHIZE DANIEL; KU, EDMOND; TODD, CHRIS; TAKAHASHI, MELISSA; JOHNSON, BRUCE; FENTON, JEFF; MORAVICK, KEITH; SPRINGBORN, UWE; DELACRUZ, ANTHONY
To: THERANOS, INC.
Reel/Frame 035888/0718 →
Continuity (8)
Continuation 11554509 · Oct 30, 2006
Continuation In Part 11388415 · Mar 24, 2006
Continuation In Part 11389410 · Mar 24, 2006
Continuation In Part 11388823 · Mar 24, 2006
Continuation In Part 11388723 · Mar 24, 2006
Continuation In Part 11388824 · Mar 24, 2006
Continuation In Part 11389409 · Mar 24, 2006
Related Publication 20140329259A1 · Nov 6, 2014